• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Samaritan Laboratories Study on Procaine's Strong Neuroprotective Properties Published By Journal of Pharmacology

Posted on: Tuesday, 26 July 2005, 09:01 CDT

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs announced today the journal of Pharmacology published a Samaritan Laboratories study suggesting procaine as exerting neuroprotective properties against Alzheimer's disease.

http://www.samaritanpharma.com/images/publocal.pdf

Dr. Janet Greeson, CEO of Samaritan stated, "Samaritan's Alzheimer's compounds are promising multi-targeted drugs. The majority of the scientific community has mainly focused on only one mechanism of action; and despite major breakthroughs in understanding disease progression there hasn't been any major advances in Alzheimer's drug development. This study reports disease progression as probably being due to the synergistic action of highly intricate networks; and procaine's neuroprotective effect is probably the result of the synergistic effect on different mechanisms of action at the same time."

There are an estimated 4.5 million people with Alzheimer's disease in the United States and by 2050 this number is projected to increase to 13.2 million. The annual direct and indirect costs, of caring for Alzheimer patients in the U.S. alone are estimated to be $100 billion. The human toll on patients, families and caregivers is incalculable.

Samaritan Pharmaceuticals: "We LIV....to Save Lives."

Samaritan Pharmaceuticals is a drug development company driven to commercialize its pipeline of innovative drugs for AIDS, Alzheimer's, CNS, Cancer and Cardiovascular disease. Samaritan, in collaboration with Georgetown University, is advancing 8 promising compounds, out of its pipeline of 250 possible drug candidates. Samaritan's patent portfolio consists of 3 issued patents and 48 pending patent applications; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

Source: Business Wire

More News in this Category